Has Erdafitinib been included in the medical insurance catalog?

Erdafitinib has been approved in many countries around the world for the targeted treatment of advanced urothelial cancer (bladder cancer). Domestically, Boco has completed marketing approval. Common specifications include 3mg 56 tablets, 4mg 28 tablets, 5mg*28 tablets, etc., which are suitable for adult patients with advanced or metastatic urothelial cancer with FGFR susceptibility gene changes. However, as of now, erdafitinib has not been included in the domestic medical insurance list, which means that patients need to bear all costs when using the drug.

Since erdafitinib is a new targeted drug, its research and development costs and prices are relatively high. If it is not included in medical insurance in the short term, the financial burden on patients will still be large. Experience in overseas markets shows that similar innovative targeted drugs are usually expensive in the early stages of marketing, but as medical insurance negotiations or generic drugs enter the market, prices and accessibility are expected to improve. In the domestic clinical environment, if patients want to use erdafitinib, they need to purchase the drug from large tertiary hospitals or specific imported drug channels. At the same time, doctors usually design individualized plans based on companion diagnostic results.

In addition, the timing of medical insurance inclusion is usually affected by multiple factors such as the accumulation of clinical use of the drug in the country, real-world efficacy data, and cost-effectiveness assessment. Although it has not yet been included in the medical insurance catalog, with the increase in patient usage data and efficacy reports, the possibility of BOC being included in medical insurance in the future will gradually increase. For patients, understanding the price and usage channels of the drug in advance, as well as participating in relevant clinical or medical insurance negotiation information, are important references for obtaining the drug.

In general, erdafitinib has been launched in China, but medical insurance coverage has not yet been achieved. Its market price and economic accessibility are still the focus of patients.

Reference materials：https://www.balversa.com/